Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the increase in clinical resistance and the persistence of resistant leukemic stem cells (LSCs). So, there is an urgent n...

Descripción completa

Detalles Bibliográficos
Autores principales: Andretta, Emanuela, Costa, Caterina, Longobardi, Consiglia, Damiano, Sara, Giordano, Antonio, Pagnini, Francesco, Montagnaro, Serena, Quintiliani, Massimiliano, Lauritano, Chiara, Ciarcia, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724906/
https://www.ncbi.nlm.nih.gov/pubmed/34993151
http://dx.doi.org/10.3389/fonc.2021.801779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724906/
https://www.ncbi.nlm.nih.gov/pubmed/34993151
http://dx.doi.org/10.3389/fonc.2021.801779

Ejemplares similares